Download by
Scanning QR Code
Download app
Download app


凤凰网港股 ·  {{timeTz}}

凤凰网港股|四环医药(00460)公布,旗下轩竹生物已收到中国国家药品监督管理局药品审评中心同意在研1类创新药吡罗西尼(Birociclib,XZP-3287 CDK4/6(细胞周期依赖性激酶4和6)抑制剂)(「吡罗西尼」)开展三期临床试验的申请,具体为:吡罗西尼与芳香化酶抑制剂联合用于激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)的局部晚期或转移性乳腺癌。于2021年8月,吡罗西尼与氟维司群的联合治疗已经获批开展三期临床试验。

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top